Renalytix plc

RENXFSEC EDGAR

Services-Medical Laboratories(X0)CIK: 1811115

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	$100.0K	—	—
Cost of Revenue	$2.7M	$2.1M	$0.00	$858.0K
Gross Profit	$720.0K	$874.0K	$0.00	$633.0K
Operating Expenses	$42.9M	$54.1M	$10.3M	-$42.3M
Operating Income (Loss)	-$42.2M	-$53.2M	-$10.3M	-$42.3M
Other Nonoperating Income (Expense)	$656.0K	—	—	$18.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$45.6M	-$45.3M	-$9.8M	—
Income Tax Expense (Benefit)	$2.0K	$25.0K	$0.00	—
Net Income (Loss) Attributable to Parent	-$45.6M	-$45.3M	-$9.8M	-$42.3M
Earnings Per Share, Basic	-$0.55

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$30.6M	$50.1M	$78.6M	$9.7M
Assets, Current	$26.9M	$44.8M	$66.8M	$9.4M
Cash and Cash Equivalents, at Carrying Value	$24.7M	$41.3M	$65.1M	$82.0K
Accounts Receivable, after Allowance for Credit Loss, Current	$776.0K	$901.0K	$594.0K	$594.0K
Liabilities	$23.7M	$19.5M	$7.1M	$1.1M
Liabilities, Current	$16.1M	$11.8M	$7.1M	$1.1M
Accounts Payable, Current	—	—	$1.4M	$317.0K
Stockholders' Equity Attributable to Parent	$30.6M	$71.5M	$8.6M	-$502.0K

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$34.1M	-$45.9M	-$9.5M	-$6.2M
Net Cash Provided by (Used in) Investing Activities	$0.00	-$662.0K	-$1.2M	-$12.3M
Net Cash Provided by (Used in) Financing Activities	$16.4M	$25.6M	$15.9M	$27.4M
Payments to Acquire Property, Plant, and Equipment	—	$557.0K	$804.0K	$309.0K
Payments for Repurchase of Common Stock	—	$8.8M	$8.8M	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)